Companies /Healthcare

LivaNova PLC

NASDAQ: LIVN Medical Devices
$92.07
▼ $2.47 (−2.61%) today
Markets closed · 5:50pm ET

LIVN at a Glance

Valuation
Market cap
$5.1B
P/E ratio
26.5
Profitability
Revenue (TTM)
$1.5B
Profit margin
13.0%
EPS (TTM)
$3.49
Price
52-week range
$53 – $99
Street target
$105.09

Headquartered in 5220 Valiant Court, Gloucester Fiscal year ends December NASDAQ: LIVN livanova.com

About LivaNova

LivaNova PLC is a global medical technology company focused on select neurological and cardiac conditions. It operates two reporting segments.

Cardiopulmonary sells heart-lung machines, including the Essenz Perfusion System, along with oxygenators and other perfusion consumables used in cardiac surgery. The company is currently expanding oxygenator manufacturing capacity to meet strong demand.

Neuromodulation centers on VNS Therapy vagus nerve stimulation devices for drug-resistant epilepsy. It also includes a proximal hypoglossal nerve stimulation therapy for moderate to severe obstructive sleep apnea, obtained via the ImThera acquisition.

The U.S. accounts for the majority of revenue, followed by Rest of World and Europe. The company has approximately 3,300 employees and a presence in more than 100 countries.

It carries legacy liabilities related to 3T Heater-Cooler litigation and the SNIA/Saluggia environmental matters, and has 2029 convertible notes outstanding. Updated

Latest Activity

LIVNLivaNova
Q3 2026
EPS
$1.23
est $1.06+16.1%
Revenue
$393M
est $381M+3.1%

Management raised full-year adjusted EPS guidance to $4.40 to $4.50 from $4.30 to $4.40 after both segments grew roughly 11%. A $34 million 3T Heater-Cooler litigation provision is the only thing holding GAAP results back.

Quarterly EPS — reported vs estimate
LIVNLivaNova PLC
Reports Wed Nov 4Before openConfirmed

Seventeen straight quarterly EPS beats go on the line at 6:00 AM ET, with consensus at $1.06 EPS on $381.11 million in revenue. The neuromodulation and cardiovascular device maker has cleared estimates by at least 6% in each of the last four quarters, so anything short of another beat resets the story.

    LIVN Coverage

    Frequently Asked Questions

    What does LivaNova do?

    LivaNova PLC is a global medical technology company focused on select neurological and cardiac conditions. It operates two reporting segments.

    What is the LIVN stock price target?

    The Wall Street consensus 12-month price target for LIVN is $105.09.